bioAffinity Technologies Inc. (NASDAQ:BIAF) stock is trading higher on Tuesday as the company announced plans to advance the application of its CyPath Lung test.
The company is pursuing the diagnostic tool for ongoing surveillance of lung cancer patients who have completed curative-intent treatment.
Addressing High Recurrence Risks In Lung Cancer
Lung cancer recurrence presents an ongoing clinical challenge. Data from the American Cancer Society showed that more than 680,000 Americans were living with a prior lung cancer diagnosis as of January 1, 2025.
In addition, the National Cancer Institute estimates that healthcare providers will diagnose 230,000 new patients in 2026.
bioAffinity Technologies focuses on noninvasive early-stage diagnostic tools for lung diseases alongside broad-spectrum cancer treatments.
How AI-Powered CyPath Lung Test Operates
CyPath Lung offers a noninvasive option to enhance early lung cancer detection in high-risk individuals.
The test utilizes advanced flow cytometry paired with proprietary artificial intelligence to identify malignant cell populations in sputum samples.
It incorporates a specialized fluorescent porphyrin that cancer and cancer-related cells preferentially absorb.
Clinical Performance and Diagnostic Potential
In published clinical trials of high-risk patients with indeterminate nodules under 20 millimeters, CyPath Lung demonstrated 92% sensitivity, 87% specificity, 88% accuracy, and a 99% negative predictive value.
These metrics reflect initial detection settings and await separate validation for post-treatment monitoring.
The high negative predictive value gives physicians greater confidence in negative results, potentially sparing patients from unnecessary and costly invasive procedures.
Marketed as a Laboratory Developed Test, CyPath Lung serves as a complementary diagnostic tool alongside other clinical findings rather than a standalone evaluation.
BIAF Price Action: bioAffinity Technologies shares were up 42.98% at $6.52 at the time of publication on Tuesday. The stock is trading near its 52-week low of $4.55, according to Benzinga Pro data.
Photo by Komsan Loonprom via Shutterstock
Login to comment